Hiroshi Tanaka
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers 19
- Pancreatic and Hepatic Oncology Research 15
- Lung Cancer Research Studies 12
- Colorectal Cancer Treatments and Studies 9
- Hepatology top 5%
-
- Lung Cancer Treatments and Mutations 24
- Lung Cancer Diagnosis and Treatment 15
- Cancer Research top 10%
- Pharmaceutical Science top 5%
-
- Neuroendocrine Tumor Research Advances 10
- Liver Disease Diagnosis and Treatment 7
- Co-authors
- Kaoru MogushiToyoaki HidaKazuhiko NakagawaTomohide TamuraYuichiro OheMakoto NishioMiyako SatouchiFengrong Ren
- Partner nations
- JapanUnited StatesChina
In The Last Decade
Hiroshi Tanaka
89 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 102
- Oncology 772
- Hepatology 175
- Pulmonary and Respiratory Medicine 519
- Cancer Research 183
- Pharmaceutical Science 71
Countries citing papers authored by Hiroshi Tanaka
This map shows the geographic impact of Hiroshi Tanaka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroshi Tanaka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroshi Tanaka more than expected).
Fields of papers citing papers by Hiroshi Tanaka
This network shows the impact of papers produced by Hiroshi Tanaka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroshi Tanaka. The network helps show where Hiroshi Tanaka may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Hiroshi Tanaka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2025 | 0 | |
| 3 | 2025 | 0 | |
| 4 | 2025 | 0 | |
| 5 | 2024 | 5 | |
| 6 | 2024 | 2 | |
| 7 | 2023 | 4 | |
| 8 | 2023 | 4 | |
| 9 | 2022 | 14 | |
| 10 | 2021 | 41 | |
| 11 | 2021 | 135 | |
| 12 | 2020 | 14 | |
| 13 | 2019 | 10 | |
| 14 | 2018 | 10 | |
| 15 | 2018 | 6 | |
| 16 | 2012 | 13 | |
| 17 | 2010 | 87 | |
| 18 | [Ten cases of advanced gastro-intestinal cancer that required preoperative dosage of PSK]. | 2009 | 1 |
| 19 | 2001 | 97 | |
| 20 | Dialysis therapy in the 1990s | 1990 | 1 |
About Hiroshi Tanaka
Hiroshi Tanaka is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Hepatology, having authored 96 papers that have together received 1.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (24 papers), Cancer Immunotherapy and Biomarkers (19 papers), Pancreatic and Hepatic Oncology Research (15 papers), Lung Cancer Diagnosis and Treatment (15 papers), Lung Cancer Research Studies (12 papers), Neuroendocrine Tumor Research Advances (10 papers), Colorectal Cancer Treatments and Studies (9 papers) and Liver Disease Diagnosis and Treatment (7 papers). The work is most often cited by research in Oncology (772 citations), Hepatology (175 citations) and Pulmonary and Respiratory Medicine (519 citations). Hiroshi Tanaka has collaborated with scholars based in Japan, United States and China. Frequent co-authors include Kaoru Mogushi, Toyoaki Hida, Kazuhiko Nakagawa, Tomohide Tamura, Yuichiro Ohe, Makoto Nishio, Miyako Satouchi, Fengrong Ren, Kenji Ikeda and Satoru Nakata. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.